Skip to main navigation Skip to search Skip to main content

Single nucleotide polymorphisms in TP53 but not KRAS or MDM2 are predictive of clinical outcome in multiple myeloma treated with high-dose melphalan and autologous stem cell support

Niklas Gebauer*, Harald Biersack, Ann Cathrin Czerwinska, Janina Schemme, Tim Tristan Hardel, Veronica Bernard, Dirk Rades, Hendrik Lehnert, Kim Barbara Luley, Christoph Thorns

*Corresponding author for this work
Original languageEnglish
JournalLeukemia and Lymphoma
Volume57
Issue number6
Pages (from-to)1482-1486
Number of pages5
ISSN1042-8194
DOIs
Publication statusPublished - 02.06.2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Cite this